Literature DB >> 19153567

Optimal timing of surgery after preoperative chemoradiotherapy for rectal cancer.

Lars Påhlman1.   

Abstract

The timing of surgery in rectal cancer treatment after neoadjuvant chemoradiotherapy is debated, mainly because of downsizing and repopulation of tumor cells. The retrospective analysis of prospectively collected data from a series of patients with locally advanced rectal cancer by Lim et al. has tried to evaluate whether timing of surgery after neoadjuvant chemoradiotherapy has any effect on tumor regression, sphincter preservation, local recurrence rate or overall survival. The study included 397 patients who had received chemoradiotherapy and surgery with different time intervals between the use of these modalities. No differences regarding all four parameters were found in patients with a time interval less or greater than 41 days. Some methodological reasons can be discussed, but the only way to answer the question of timing is, of course, to do a randomized trial.

Entities:  

Year:  2009        PMID: 19153567     DOI: 10.1038/ncponc1325

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  4 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome?

Authors:  Angelita Habr-Gama; Rodrigo Oliva Perez; Igor Proscurshim; Rafael Miyashiro Nunes Dos Santos; Desiderio Kiss; Joaquim Gama-Rodrigues; Ivan Cecconello
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-01-30       Impact factor: 7.038

3.  Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study.

Authors:  Calin Radu; Ake Berglund; Lars Påhlman; Bengt Glimelius
Journal:  Radiother Oncol       Date:  2008-02-21       Impact factor: 6.280

4.  Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.

Authors:  Seok-Byung Lim; Hyo Seong Choi; Seung-Yong Jeong; Dae Yong Kim; Kyung Hae Jung; Yong Sang Hong; Hee Jin Chang; Jae-Gahb Park
Journal:  Ann Surg       Date:  2008-08       Impact factor: 12.969

  4 in total
  5 in total

1.  Does the timing of esophagectomy after chemoradiation affect outcome?

Authors:  Jae Y Kim; Arlene M Correa; Ara A Vaporciyan; Jack A Roth; Reza J Mehran; Garrett L Walsh; David C Rice; Jaffer A Ajani; Dipen M Maru; Manoop S Bhutani; James Welsh; Edith M Marom; Stephen G Swisher; Wayne L Hofstetter
Journal:  Ann Thorac Surg       Date:  2011-10-01       Impact factor: 4.330

2.  Waiting Time following Neoadjuvant Chemoradiotherapy for Rectal Cancer: Does It Really Matter.

Authors:  Aris Plastiras; Michail Sideris; Andy Gaya; Amyn Haji; Joseph Nunoo-Mensah; Asif Haq; Savvas Papagrigoriadis
Journal:  Gastrointest Tumors       Date:  2017-12-15

3.  Optimal timing of surgery after neoadjuvant chemoradiation therapy in locally advanced rectal cancer.

Authors:  Duck Hyoun Jeong; Han Beom Lee; Hyuk Hur; Byung Soh Min; Seung Hyuk Baik; Nam Kyu Kim
Journal:  J Korean Surg Soc       Date:  2013-05-28

4.  Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial.

Authors:  Meng-Xia Zhang; Xiao-Bo Li; Bing-Jie Guan; Guo-Xian Guan; Xiao-Yan Lin; Xiao-Dong Wu; Pan Chi; Ben-Hua Xu
Journal:  BMJ Open       Date:  2019-03-23       Impact factor: 2.692

5.  Optimal interval to surgery after chemoradiotherapy in rectal cancer: A protocol for systematic review and network meta-analysis.

Authors:  Ya Jing Chen; Zhen-Jie Zhao; Bang Wei Wang; Guang Zhuang Jing; Hai-Kun Ma; Xuemei Han; Jiancheng Wang; Zhen-Jie Zhao
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.